Connect with us

Press Release

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Published

on

–News Direct–

By James Blacker, Benzinga

Some 42% of adults in the United States are affected by obesity, according to the U.S. CDC. At a global level, a new study released by the journal Lancet reveals that around 1 billion people are now living with obesity, with the number of obese adults having doubled since 1990 and quadrupled among children and adolescents.

The demand for solutions to escalating obesity rates is only growing. Goldman Sachs Research notes that the global market for anti-obesity drugs reached $6 billion on an annualized basis in 2023 and this global market is projected to experience a more than 16-fold increase to $100 billion by 2030. The global growth of anti-obesity drugs is expected to be led by drugs such as Ozempic and Wegovy, both manufactured by Novo Nordisk (NYSE: NVO), as well as Mounjaro, made by Eli Lilly And Co (NYSE: LLY).

However, there are concerns that GLP-1 drugs like Ozempic and Wegovy might lead to a loss of muscle mass along with fat mass. This potential side effect highlights a need for new or coinciding treatments that can address obesity while limiting such side effects.

Revolutionizing Obesity Treatment

Medical aesthetics and biopharmaceutical drug development company Elevai Labs Inc. (NASDAQ: ELAB) is working to address this problem. The firm announced on May 2 that it acquired exclusive rights to two new assets that have the potential to limit muscle loss prevention to develop in combination with GLP-1 obesity treatments namely EL-22, a clinical-stage engineered probiotic expressing myostatin, and EL-32, a preclinical engineered probiotic expressing dual myostatin & activin-A.

We believe the adoption and use of other GLP-1 drugs [] increases the desire for related aesthetic procedures linked to the side effects from these drugs, including significant unwanted muscle loss. We see the licensing of these two assets as an opportunity to provide an unmet need in the anti-obesity drug market and expand our brand into a large and growing multi-billion-dollar market, said Elevai Labs CEO Jordan R. Plews.

Elevai plans to test how effective and safe EL-22 is in combination with weight-loss medications currently available on the market. It expects to submit an Investigational New Drug application to the FDA in 2025 and hopes to initiate clinical trials in the U.S. soon thereafter.

New Subsidiaries

In line with its growth in the biotech industry, Elevai Labs announced on May 1 it launched two new wholly-owned subsidiaries Elevai Biosciences and Elevai Skincare.

Elevai Biosciences will focus on acquiring and developing cutting-edge aesthetic medicines, with EL-22 as its lead asset.

Elevai Skincare is a new entity that will continue to advance the companys skincare solutions. The company hopes that the reorganization of its skincare operations will boost focus, agility, and market penetration in order to capitalize on emerging opportunities in the medical aesthetics skincare market.

Commenting on the announcement, Co-founder and CEO Jordan R. Plews stated, The launch of Elevai Biosciences, Inc. and Elevai Skincare, Inc. as wholly-owned operating subsidiaries signifies a significant milestone in our journey towards reshaping the future of medical aesthetics and biotech. With Elevai Biosciences, we believe we are poised to lead the development of next-generation aesthetic medicines, while Elevai Skincare will continue to develop and deliver exceptional cosmetic solutions to our customers worldwide.

Featured photo by Prostock-studio on Shutterstock.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Elevai's expectations regarding its growth, strategy, progress and the design, objectives and timing of its clinical trials for EL-22; and the potential of EL-22 to treat obesity without an associated loss of muscle, both as a monotherapy and in combination with GLP-1 receptor agonists. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Elevai's limited operating history and historical losses; Elevai's ability to raise additional funding to complete the development and any commercialization of its product candidates; Elevai's dependence on the success of its product candidates EL-22 and EL-32; that Elevai may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Elevai's ability to obtain, maintain and protect its intellectual property; and Elevai's dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in Elevai's filings with the Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Benzinga

+1 877-440-9464

info@benzinga.com

Company Website

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/elevai-labs-nasdaq-elab-acquires-rights-to-develop-muscle-loss-prevention-assets-for-anticipated-use-in-anti-obesity-treatments-launches-two-new-subsidiaries-108007273

Benzinga

comtex tracking

COMTEX_452512161/2655/2024-05-17T08:49:56

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Exclusive Markets Receives Top Honors at International Business Magazine Awards 2024

Published

on

Dubai, UAE, 25th October 2024, ZEX PR WIRE, Exclusive Markets, a globally renowned leader in online multi-asset trading, has once again showcased its commitment to excellence by holding several prestigious awards at the highly esteemed International Business Magazine Awards 2024. The company has emerged victorious in the following categories:

  • Most Trusted Forex Broker Global 2024
  • Best FX Broker Global 2024
  • Best Customer Support Global 2024
  • Best Partners Program Global 2024
  • Most Transparent Broker Asia 2024

These esteemed awards reaffirm Exclusive Markets’ steady dedication to setting new benchmarks in the industry and delivering unmatched service to its worldwide clientele. The company’s forward-thinking strategies, which are always at the forefront of industry trends, its emphasis on transparency, and its unwavering focus on providing exceptional experiences for traders and partners have set it apart in the fiercely competitive market.

The official award presentation is scheduled to take place at the prestigious Grand Annual Awards Ceremony 2024 in the luxurious Atlantis, The Palm, Dubai, UAE, later this year. This highly anticipated event, set for Q4, will bring together top professionals from the global finance industry to celebrate outstanding achievements and innovation.

Hemant Kumar, Exclusive Markets’ CMO, expressed his gratitude, remarking, “Securing 5 prestigious awards is a testament to our relentless pursuit of excellence and the firm trust that our clients and partners have placed in us. Our entire team has worked tirelessly to uphold these values, and we take immense pride in seeing our efforts acknowledged on such a prestigious platform.”

With these remarkable awards, Exclusive Markets has further solidified its position as a revered leader in the Forex trading industry, strengthening its reputation as a company that prioritizes partnerships and remains dedicated to delivering unparalleled client satisfaction!

About Exclusive Markets

Exclusive Markets is dedicated to providing traders with a robust, secure, and transparent platform for investing in a variety of financial instruments. With a focus on cutting-edge technology and holding ISO/IEC 27001:2013 Certification by MSECB, Exclusive Markets offers traders an exceptional platform that seamlessly integrates advanced features with user-friendly interfaces.

Traders can access a wide array of trading instruments, including CFD stocks, commodities, forex, and spot metals. The company’s expert team is committed to meeting the evolving needs of its clients by continually expanding its range of products and services, allowing traders to invest according to their preferences.

Risk Warning: Trading involves risk.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

AVIDLOVE Unveils Hauntingly Good Halloween Deals: Cosplay Costumes and Lingerie for a Spooky Night

Published

on

Chino, CA, United States, 25th Oct 2024 – AVIDLOVE, known for its chic and high-quality lingerie, is unveiling its 2024 Halloween Collection, which promises to make this Halloween more exciting and fashionable than ever before. 

With a perfect blend of cosplay costumes and lingerie, this collection offers the ultimate combination of spooky and sexy to elevate the festive wardrobe. During the Halloween event, customers can get 20%-50% off their costumes at Amazon.  At the same time, the event will also be accompanied by the release of the brand video, which can fully demonstrate the corporate image.

A Collection That Captures the Spirit of Halloween

The AVIDLOVE 2024 Halloween Collection is designed to embody the spirit of Halloween with a range of playful, mysterious, and stylish lingerie and cosplay costumes. 

AVIDLOVE’s offerings range from lace babydolls and underwire bodysuits to garter sets and pleated mini skirts, all featuring Halloween-themed designs that include skulls, pumpkins, bats, and more.

For those who enjoy embracing the darker, edgier side of the holiday, AVIDLOVE offers styles such as fishnet lingerie, spider-web bodysuits, and even ruffled skirts that perfectly fit the eerie Halloween vibe.

Cosplay-Inspired Lingerie of AVIDLOVE

Halloween is not just about trick-or-treating or spooky decorations — it’s a time to explore fun and creativity through costumes. AVIDLOVE’s collection offers a variety of cosplay-inspired lingerie sets that bring fantasy to life. 

These cosplay costumes are designed with attention to detail, ensuring that customers feel both confident and comfortable throughout the night. The collection also includes garter chemises, role-play mini skirts, and lace slip dresses, all of which combine a flirtatious edge with high-quality fabrics that feel great against skin. 

Find Perfect Look Easily in AVIDLOVE

AVIDLOVE’s user-friendly website makes it incredibly simple to shop and find the perfect lingerie or costume for Halloween. With detailed product descriptions and high-quality images, customers can easily browse the collection and discover what suits their style. The website also offers a size guide and helpful FAQs, ensuring that customers find the right fit and feel confident with their purchase.

AVIDLOVE is dedicated to providing a worry-free shopping experience, and its responsive customer service team is always available to answer questions or assist with orders. With free shipping on qualifying orders and easy return policies, shopping with AVIDLOVE is as convenient as it is enjoyable.

About AVIDLOVE

AVIDLOVE is a leading brand in the world of lingerie and sleepwear, known for its superb quality, fit, and style. The brand offers a wide range of lingerie, sleepwear, and more, with collections that cater to every occasion and personal style. AVIDLOVE’s mission is to help individuals feel confident and empowered through its fashion-forward designs. 

The 2024 Halloween Collection continues this tradition, offering stylish and spooky costumes and lingerie that make Halloween a celebration of self-expression and creativity. Explore the full collection at AVIDLOVE.com and discover how it can bring the magic and mystery of Halloween to life with the perfect outfit. 

Get stocking stuffers with subscription and a surprise mystery package: $24.99 Halloween Blind Box (free with $99 or more) in AVIDLOVE’s independent station Exclusive Halloween Costume Event. 

For more information about the campaign and upcoming promotions, visit AVIDLOVE’s Official Website.

Media Contact

Organization: AVIDLOVE

Contact Person: Hillen Dogwa

Website: https://avidlove.com/

Email: service@avidlove.com

City: Chino

State: CA

Country: United States

Release Id: 25102418848

The post AVIDLOVE Unveils Hauntingly Good Halloween Deals: Cosplay Costumes and Lingerie for a Spooky Night appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Calmerry, an online therapy platform, welcomes Janine Ellenberger as a Strategic Advisor to elevate therapist training and client care

Published

on

Calmerry Welcomes Dr Janine Ellenberger, as Strategic Advisor to Support Growth and Innovation in Online Therapy

New Castle, Delaware, United States, 25th Oct 2024 – Calmerry, an innovative provider of flexible and accessible online therapy services, is excited to announce the addition of Dr. Janine Ellenberger, as Strategic Advisor. With over 20 years experience as a physician, entrepreneur, and health executive, Janine brings a wealth of experience in helping scale visionary digital health solutions to Calmerry, further enhancing its ability to deliver high-quality mental health care.

Janine’s career spans clinical practice, digital health, leadership, and strategic development. She is currently the Co-Founder and Chief Medical Officer of Behavidence, a cutting-edge company that leverages machine learning to monitor mental health conditions through digital biomarkers. Her global experience and expertise will provide Calmerry with invaluable guidance as the company continues to revolutionize mental health care.

“We are thrilled to welcome Janine to our team,” said Alex Vitchenko, Founder & CEO at Calmerry. “Her passion for improving access to quality care, combined with her strategic vision, aligns perfectly with Calmerry’s mission of offering personalized and flexible online mental health services.”

In her new advisory role, Janine will offer high-level strategic guidance across two key initiatives at Calmerry:

1. Ensuring Excellence in Virtual Therapy Training: Janine will provide direction to the teams responsible for developing and maintaining comprehensive training programs for therapists. These programs will enhance therapists’ ability to deliver effective virtual care, building on their existing offline experience to raise the overall standard of online therapy.

2. Precision Matching of Therapists and Clients: Leveraging Calmerry’s proprietary algorithms, Janine will guide the ongoing refinement of the platform’s therapist-client matching process. Her focus will be on ensuring that clients receive highly personalized care by improving the accuracy and efficiency of matching therapists to clients based on individual needs and specialties.

In addition to these initiatives, Janine will contribute to Calmerry’s broader strategic goals by offering insights into product roadmap development and market growth. She will also support the company’s efforts to expand insurance coverage for its services, making online therapy even more accessible to clients across the U.S.

“I’m excited to join Calmerry and contribute to its mission of transforming mental health care,” said Janine.  “My goal is to ensure that clinicians are empowered to provide the highest quality virtual care, and that clients are matched with the right therapists for their individual needs. This precision  matching of the right care at the right time is what sets Calmerry apart from the rest! I look forward to working with the team to drive innovation, growth and impact.”

Janine’s extensive experience in navigating complex health systems, will play a key role in ensuring the success of these initiatives and positioning Calmerry as a leader in the digital mental health space.

About Calmerry:

Calmerry is an innovative online therapy platform that connects clients with licensed therapists, providing accessible and personalized mental health services. Committed to enhancing the quality of care, Calmerry is at the forefront of transforming the mental health landscape through technology.

For more information visit https://calmerry.com/

Media Contact

Organization: Calmerry

Contact Person: George Thompson

Website: https://calmerry.com/

Email: Send Email

Contact Number: +18447402144

City: New Castle

State: Delaware

Country: United States

Release Id: 25102418771

The post Calmerry, an online therapy platform, welcomes Janine Ellenberger as a Strategic Advisor to elevate therapist training and client care appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST